

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Bao Nguyen^{1,*}, Allen B. Williams^{1,*}, David J. Young^{1,2}, Hayley Ma¹, Li Li¹, Mark Levis¹, Patrick Brown^{1,2} and Donald Small^{1,2}

¹ Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

² Department of Pediatrics Johns Hopkins University School of Medicine, Baltimore, MD, USA

* These authors have contributed equally to this work

Correspondence to: Donald Small, **email:** donsmall@jhmi.edu

Keywords: acute myeloid leukemia, mutant FLT3, activation loop, tyrosine kinase inhibitors

Received: December 16, 2016

Accepted: December 25, 2016

Published: January 06, 2017

Supplemental Table 1. Primer sequences

D835A-F, GTGACTTTGGATTGGCTCGAGCTATCATGAGTGATTCCAAC;

D835A-R, GTTGAATCACTCATGATAGCTCGAGCCAATCCAAAGTCAC;

D835G-F, GTGACTTTGGATTGGCTCGAGGTATCATGAGTGATTCCAAC;

D835G-R, GTTGAATCACTCATGATAGCTCGAGCCAATCCAAAGTCAC;

D835N-F, GTGACTTTGGATTGGCTCGAAATATCATGAGTGATTCCAAC;

D835N-R, GTTGAATCACTCATGATATTTTCGAGCCAATCCAAAGTCAC;

D835L+K-F, GTGACTTTGGATTGGCTCGACTTAAAATCATGAGTGATTCCAAC;

D835L+K-R, GTTGAATCACTCATGATTTTAAGTCGAGCCAATCCAAAGTCAC;

D835Y-F, GTGACTTTGGATTGGCTCGATATATCATGAGTGATTCCAAC;

D835Y-R, GTTGAATCACTCATGATATATCGAGCCAATCCAAAGTCAC;

I836L+D-F, GTGACTTTGGATTGGCTCGAGATCTCGACATGAGTGATTCCAAC;

I836L+D-R, GTTGAATCACTCATGTCTCGAGATCTCGAGCCAATCCAAAGTCAC;

I836S-F, GTGACTTTGGATTGGCTCGAGATAGCATGAGTGATTCCAAC;

I836S-R, GTTGAATCACTCATGCTATCTCGAGCCAATCCAAAGTCAC;

I836T-F, GTGACTTTGGATTGGCTCGAGATACCATGAGTGATTCCAAC;

I836T-R, GTTGAATCACTCATGGTATCTCGAGCCAATCCAAAGTCAC;

840G+S-F, GATATCATGAGTGATTCCGGCAGCAACTATGTTGTCAGGGGCAAT;

840G+S-R, ATTGCCCTGACAACATAGCCGTTGCTGGAATCACTCATGATATC.